Tag: HPQ

Diversified Tech

Eye Catching Stocks: LyondellBasell Industries (NYSE:LYB), Hewlett-Packard Company (NYSE:HPQ), The Hackett Group (NASDAQ:HCKT), Ruckus Wireless (NYSE:RKUS), Lifepoint Hospitals Inc. (NASDAQ:LPNT)

LyondellBasell Industries NV (NYSE:LYB) Director Milton Carroll sold 2,720 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $90.76, for a total value of $246,867.20. LyondellBasell Industries N.V. (NYSE:LYB) belongs to Basic Materials sector. Its net profit margin is 9.80% and weekly performance is -12.78%. On last trading day company shares ended … Continue reading Eye Catching Stocks: LyondellBasell Industries (NYSE:LYB), Hewlett-Packard Company (NYSE:HPQ), The Hackett Group (NASDAQ:HCKT), Ruckus Wireless (NYSE:RKUS), Lifepoint Hospitals Inc. (NASDAQ:LPNT)

John Meady
Finance

5 Stocks Under Wall Street’s Radar: Hewlett-Packard Company (NYSE:HPQ), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Banco Santander, S.A. (NYSE:SAN), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), PKG

Jefferies Group initiated coverage on shares of Hewlett-Packard Company (NYSE:HPQ) in a research report released on Thursday, TheFlyOnTheWall.com reports. The firm issued a hold rating and a $38.00 price objective on the stock. Hewlett-Packard Company (NYSE:HPQ) belongs to Technology sector. Its net profit margin is 4.50% and weekly performance is 1.39%. On last trading day company shares ended up $36.38. Hewlett-Packard Company (NYSE:HPQ) distance from … Continue reading 5 Stocks Under Wall Street’s Radar: Hewlett-Packard Company (NYSE:HPQ), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Banco Santander, S.A. (NYSE:SAN), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), PKG

Chris Lewis
Finance

Morning Alert: Repros Therapeutics Inc. (NASDAQ:RPRX), Hewlett-Packard Company (NYSE:HPQ), Flowers Foods, Inc. (NYSE:FLO), American River Bankshares (NASDAQ:AMRB), Delta Air Lines, Inc. (NYSE:DAL)

Repros Therapeutics Inc. (NASDAQ:RPRX) on Oct. 21 reported results from a large, controlled, long-term safety study comparing Androxal(R) to a placebo. In this study of Androxal(R), ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal(R)-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. Repros Therapeutics Inc. … Continue reading Morning Alert: Repros Therapeutics Inc. (NASDAQ:RPRX), Hewlett-Packard Company (NYSE:HPQ), Flowers Foods, Inc. (NYSE:FLO), American River Bankshares (NASDAQ:AMRB), Delta Air Lines, Inc. (NYSE:DAL)

Mark Doerr